Jupiter Bioscience Ltd
Jupiter Bioscience Limited manufactures drug intermediates, specialty and fine chemicals, bulk drugs, and nutraceuticals primarily in India. The company offers aminoacids and its derivatives, including Fmoc-, Boc-, and Z-protected aminoacids, as well as side chain protected aminoacids.
- Market Cap ₹ Cr.
- Current Price ₹ 3.97
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 128
- Dividend Yield 0.00 %
- ROCE 6.66 %
- ROE 6.44 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.03 times its book value
Cons
- Tax rate seems low
- Company has a low return on equity of 7.94% over last 3 years.
- Dividend payout has been low at 12.6% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| 80 | 104 | 130 | 143 | 184 | 253 | |
| 45 | 59 | 71 | 70 | 88 | 143 | |
| Operating Profit | 35 | 45 | 58 | 73 | 96 | 110 |
| OPM % | 44% | 44% | 45% | 51% | 52% | 43% |
| 0 | 0 | 1 | 2 | 0 | 0 | |
| Interest | 4 | 7 | 11 | 17 | 23 | 26 |
| Depreciation | 9 | 13 | 17 | 26 | 35 | 44 |
| Profit before tax | 22 | 25 | 31 | 32 | 37 | 40 |
| Tax % | 22% | 26% | 14% | 12% | 11% | 6% |
| 17 | 19 | 27 | 28 | 33 | 38 | |
| EPS in Rs | 19.07 | 14.91 | 17.47 | 20.54 | 6.02 | |
| Dividend Payout % | 13% | 12% | 13% | 11% | 10% | 17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 25% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 12% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 18 | 16 | 16 | 62 |
| Reserves | 105 | 157 | 284 | 310 | 353 | 736 |
| 90 | 165 | 190 | 277 | 394 | 404 | |
| 20 | 19 | 28 | 29 | 26 | 45 | |
| Total Liabilities | 223 | 351 | 520 | 632 | 789 | 1,248 |
| 68 | 108 | 192 | 256 | 319 | 369 | |
| CWIP | 26 | 55 | 80 | 94 | 139 | 174 |
| Investments | 55 | 86 | 126 | 148 | 178 | 503 |
| 75 | 101 | 122 | 134 | 153 | 203 | |
| Total Assets | 223 | 351 | 520 | 632 | 789 | 1,248 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| 28 | 16 | 43 | 58 | 70 | 89 | |
| -54 | -114 | -165 | -124 | -173 | -471 | |
| 26 | 100 | 122 | 65 | 106 | 382 | |
| Net Cash Flow | 0 | 1 | -1 | -1 | 3 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Debtor Days | 78 | 89 | 92 | 98 | 87 | 92 |
| Inventory Days | 199 | 295 | 342 | 435 | 366 | 231 |
| Days Payable | 5 | 5 | 6 | 45 | 26 | 26 |
| Cash Conversion Cycle | 272 | 379 | 429 | 487 | 427 | 297 |
| Working Capital Days | 116 | 191 | 216 | 245 | 244 | 205 |
| ROCE % | 12% | 10% | 9% | 9% | 7% |
Documents
Announcements
No data available.